^
Association details:
Biomarker:XAGE1 antibody elevation
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

A Novel Automated Immunoassay for Serum NY-ESO-1 and XAGE1 Antibodies in Combinatory Prediction of Response to Anti-Programmed Cell Death-1 Therapy in Non-Small-Cell Lung Cancer

Published date:
04/15/2021
Excerpt:
Sera from 30 NSCLC patients before anti-PD-1 monotherapy were reacted with recombinant NY-ESO-1 protein- or synthetic XAGE1 peptide-coated magnetic beads....The Ab levels in 15 NSCLC responders to anti-PD-1 monotherapy were significantly higher than those in non-responders and healthy donors. The AUROC was the highest (0.91; 95% CI, 0.78-1.0) in combinatory prediction with NY-ESO-1/XAGE1 Abs.
DOI:
https://doi.org/10.1016/j.cca.2021.04.008